tbuckley/cabot-search huggingface dataset:
Posttraumatic stress disorder among frontline soldiers with combat stress reaction: the 1982 Israeli experience
Authors: Z Solomon, M Weisenberg, J Schwarzwald, M Mikulincer
Journal: American Journal of Psychiatry (1987)

One year after the 1982 Lebanon War, the authors assessed the prevalence, type, and severity of posttraumatic stress disorder in a large representative sample of Israeli soldiers who had been treated for combat stress reactions. Comparisons were made with a group of soldiers who had fought in the same battles but had not been treated for this reaction. A dramatically higher percentage of soldiers with combat stress reaction (59%) than of soldiers without combat stress reaction (16%) developed posttraumatic stress disorder. Age was significantly associated with posttraumatic stress disorder. The authors discuss the differential quality of posttraumatic stress disorder among both groups as well as the factors facilitating recovery.
Need for Alpha-Fetoprotein Assays
Authors: R S Amato
Journal: New England Journal of Medicine (1976)

An alpha fetoprotein assay is useful in diagnosing open neural-tube defects. The U.S. Food and Drug Administration is urged to establish guidelines for reagent licensing so that this test can be available throughout the country. Correct data for fetuses of 15-16 weeks' gestation are now complete. With this data and available alpha fetoprotein, the test could be run at individual medical centers and hospitals.
Association of Setmar Expression with Clinical Characteristics in Chronic Lymphocytic Leukemia
Authors: Flavia Z Piazera, Doralina Amaral Rabello, Felipe Araújo Saldanha, Fábio Pitella Silva, Fábio Morato Oliveira, Antonio R. Lucena-Araujo, Eduardo Magalhães Rego
Journal: Blood (2015)
Platelet-Derived Proteases ADAM10 and ADAM17 Impair NK Cell Immunosurveillance of Metastasizing Tumor Cells By Diminishing NKG2D Ligand Surface Expression
Authors: Stefanie Raab, Korbinian Nepomuk Kropp, Alexander Steinle, Gerd Klein, Lothar Kanz, Hans-Georg Kopp, Helmut R Salih
Journal: Blood (2014)
Correlation of Inhibition of Adhesion of Large Cell Lymphoma and Hepatic Sinusoidal Endothelial Cells by RGD-Containing Peptide Polymers with Metastatic Potential: Role of Integrin-Dependent and -Independent Adhesion Mechanisms
Authors: R J Tressler, P N Belloni, G L Nicolson
Journal: Cancer Communications (1989)

Murine RAW117 large-cell lymphoma cells that show organ preferences of metastatic colonization were selected. We examined the role of adhesive systems in determining the organ preference of metastasis using cell lines of low (RAW117-P) and high (RAW117-H10) liver-metastatic potential. Highly metastatic H10 cells adhered at higher rates than low metastatic P cells to target organ microvessel endothelial cells, and these interactions were partially inhibited by RGD-containing polymers but not by small peptides such as GRGDS or GRGES. The most effective polymers, such as (GRGDS)4 and GRGDS(GRGES)2GRGDS, significantly inhibited H10 cell adhesion but had less effect on P cell adhesion to target liver sinusoidal endothelial cell monolayers or on P cell or H10 cell adhesion to bovine aortic endothelial cell monolayers. The (GRGDS)4 polymer reduced the rate of H10 liver sinusoidal endothelial cell adhesion to that of P cells in the absence of inhibitors, suggesting that the quantitative difference in adhesion of H10 cells versus P cells to liver sinusoidal endothelial cells may have been due to integrin-like molecules. Other RGD-containing polymers, such as (GRGES)2(GRGDS)2, GRGES(GRGDS)2GRGES, or (GRGES)4, were less effective, suggesting that the secondary structure of the polymers may be an important consideration. A peptide from the B1 chain of laminin (YIGSR) or its homopolymer, (YIGSR)4, had no effect on endothelial cell adhesion, consistent with the lack of differential laminin adhesion seen with various RAW117 cell lines. The results suggest that integrin-related molecules may play a role in the organ specificity of endothelial cell adhesion seen with RAW117 tumor cells.
Final results of feasibility study of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) for clinical stage II/III esophageal squamous cell carcinoma.
Authors: H. Hara, H. Daiko, K. Kato, H. Igaki, S. Kadowaki, Y. Tanaka, Y. Hamamoto, H. Matsushita, M. Nagase, Y. Hosoya, M. Tahara
Journal: Journal of Clinical Oncology (2011)

4060 Background: The results of JCOG 9907 randomized trial of neoadjuvant chemotherapy with cisplatin plus 5-fluorouracil (CF) vs. adjuvant CF for stage II/III esophageal squamous cell carcinoma (ESCC) shows a survival advantage of neoadjuvant CF over adjuvant CF. However, survival of neoadjuvant CF remains limited. Therefore, we conducted a feasibility study of a neoadjuvant chemotherapy with docetaxel plus CF (DCF) for clinical stage II/III ESCC. Methods: Eligibility criteria included stage II/III (non T4) ESCC, PS 0-1, and 20-75 years old. Chemotherapy consisted of a 1-h infusion of docetaxel at 70-75 mg/m2, 2-h infusion of cisplatin at 70-75 mg/m2 on day 1, and continuous infusion of 5-FU 750 mg/m2/day (CIV) on day 1 to 5. Antibiotic prophylaxis on days 5 to 15 was mandatory. This regimen was repeated every 3 weeks, with a maximum of 3 cycles allowed until unacceptable toxicity, patient refusal or disease progression was observed. After completion of chemotherapy, esophagectomy with extended (>D2) lymphadenectomy was performed. The primary endpoint was the completion rate of protocol treatment. Results: From July 2009 to May 2010, 44 pts were enrolled including 2 ineligibles. In 42 eligible pts, the median age was 62 (range 36-73); male/female: 40/2; PS0/1: 28/14; cStage IIA/IIB/III : 9/9/24. During chemotherapy, most common grade 3 or 4 toxicities were neutropenia (83%), febrile neutropenia (2%), anorexia (7%), and stomatitis (5%). Forty one (98%) pts underwent surgery. The completion rate of protocol treatment was 90.5 % (38/42). No treatment related death was observed and the incidence of operative morbidity was comparable to that of previous studies. According to RECIST, overall response rate was 60.0% (18/30) after completion of DCF. Pathological CR was achieved in 22% (9/41) of the pts who received an esophagectomy. Conclusions: Neoadjuvant DCF was well tolerated and antitumor activity was highly promising. We are preparing a three-arm phase III trial comparing CF, DCF and chemoradiotherapy as a neoadjuvant therapy for locally advanced ESCC.
Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid
Authors: Glenn J. Jaffe, Peter K. Kaiser, Desmond Thompson, Andrea Gibson, Namrata Saroj, Robert Vitti, Alyson J. Berliner, Jeffrey S. Heier
Journal: Ophthalmology (2016)

To compare the effect of intravitreal aflibercept or ranibizumab drug type and frequency on visual acuity outcomes in eyes with neovascular age-related macular degeneration (NVAMD) and early persistent retinal fluid after 3 initial monthly injections.A post hoc analysis of eyes enrolled in VIEW 1 and VIEW 2, 2 similarly designed, randomized, phase 3 trials.A total of 1815 eyes with NVAMD from VIEW 1 and VIEW 2.Analyses included patients with known fluid status at baseline and weeks 4, 8, and 12 in 3 treatment groups: ranibizumab 0.5 mg every 4 weeks (Rq4) (n = 595), intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4) (n = 613), and IAI 2 mg every 8 weeks (2q8) after 3 monthly injections (n = 607).Mean best-corrected visual acuity (BCVA) change from baseline over weeks 16 to 52 and the proportion of eyes that gained ≥15 letters or lost ≥5 letters were evaluated in eyes with and without persistent fluid (cystic intraretinal or subretinal fluid at all 4 initial visits). Visual outcomes also were assessed in eyes with persistent fluid by fluid type (intraretinal and subretinal fluid).The proportions of eyes with persistent fluid were 29.4%, 18.8%, and 20.3% in the Rq4, 2q4, and 2q8 groups, respectively. In these eyes, mean BCVA gain from baseline to week 52 was greater with 2q4 compared with Rq4 (P < 0.01) and 2q8 (P < 0.05), whereas it was similar with Rq4 and 2q8 (P = 0.294). At week 52, similar proportions of eyes gained ≥15 letters (31.5%-35.2%), whereas fewer eyes lost ≥5 letters with 2q4 compared with Rq4 and 2q8 (6.5% vs. 16.6% and 16.2%). The pattern of visual outcomes was similar regardless of fluid type. In eyes without persistent fluid, BCVA changes were similar across treatment groups.In patients with early persistent fluid, 2q4 may provide additional clinical benefit over 2q8 or Rq4.
Correction: Article on CD44 As a Marker of Colorectal Cancer Stem Cells
Journal: Clinical Cancer Research (2008)

In the article by Du and colleagues entitled “CD44 is of functional importance for colorectal cancer stem cells,” published in the November 1, 2008, issue of Clinical Cancer Research, Figs. 1, 2, 3, and 4 should have been published in full color rather than grayscale. The figures are reproduced correctly in the next pages, in full color. Du L, Wang H, He L, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008;14:6751–60.
Cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion (HIPEC): Toxicity, survival, and prognostic variables in 130 patients with peritoneal carcinomatosis
Authors: W. Ceelen, M. Peeters, P. Houtmeyers, C. Breusegem, F. De Somer, P. Pattyn
Journal: Journal of Clinical Oncology (2007)

15040 Background: Peritoneal carcinomatosis (PC) has a dismal prognosis. Cytoreductive surgery with HIPEC has been introduced in the management of PC with biologically favourable features. Methods: In an eight year period, 130 patients were treated (53% female, mean age 56±1 years). The origin of PC was colorectal cancer (CRC, 58%), pseudomyxoma peritonei (PMP, 9%), ovarian cancer (17%), primary peritoneal mesothelioma (10%) and gastric cancer (6%). Surgery was followed by HIPEC with mitomycin C (90 min, 35 mg/m 2 ), oxaliplatin (30 min, 460 mg/m 2 ) or cisplatin (90 min, 100–250 mg /m 2 ) depending on tumour histology and previous systemic chemotherapy. The extent of disease was scored using a scale ranging from 0–9, while completeness of cytoreduction (CC) was scored as complete (CC0), nearly complete (CC1, miliary residual disease) or incomplete (CC2, gross residual disease). Target intraperitoneal temperature was 41°C-42°C. Actuarial survival was calculated using the Kaplan Meier method and univariate analysis performed using the log rank method. Results: Open perfusion (coliseum technique) was used in 41% of procedures. Macroscopically complete resection was achieved in 41%. Postoperative 30 day mortality was 1.5% while major morbidity developed in 18% of patients. Morbidity was mainly related to the extent of surgery. Median overall survival (months) was as follows: CRC, 20; PMP, 38; ovarian cancer, 19; gastric cancer, 10; mesothelioma, 9. Median survival was significantly better in CC0 patients (40 months) compared to CC1 (17 months) or CC2 (12 months). Survival was significantly worse in patients with ascites at surgery (p&lt;0.02) and in patients who did not receive adjuvant systemic chemotherapy (p&lt;0.001). The extent of disease score before surgery (p=0.29), performance of a splenectomy (p=0.65), and timing of PC (metachronous or synchronous, p=0.25) were not significantly related to overall survival. Conclusions: Cytoreduction followed by HIPEC offers a significant survival advantage in selected patients with PC with acceptable early toxicity. Survival is significantly associated with disease histology, CC, presence of ascites and adjuvant chemotherapy. No significant financial relationships to disclose.
Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial
Authors: Toru Sugiyama, Aikou Okamoto, Takayuki Enomoto, Tetsutaro Hamano, Eriko Aotani, Yasuhisa Terao, Nao Suzuki, Mikio Mikami, Nobuo Yaegashi, Kiyoko Kato, Hiroyuki Yoshikawa, Yoshihito Yokoyama, Hiroshi Tanabe, Koji Nishino, Hiroyuki Nomura, Jae-Weon Kim, Byoung-Gie Kim, Sandro Pignata, Jerome Alexandre, John Green, Seiji Isonishi, Fumitoshi Terauchi, Keiichi Fujiwara, Daisuke Aoki
Journal: Journal of Clinical Oncology (2016)

Clear cell carcinoma (CCC) is a rare histologic subtype that demonstrates poor outcomes in epithelial ovarian cancer. The Japanese Gynecologic Oncology Group conducted the first randomized phase III, CCC-specific clinical trial that compared irinotecan and cisplatin (CPT-P) with paclitaxel plus carboplatin (TC) in patients with CCC.Six hundred sixty-seven patients with stage I to IV CCC of the ovary were randomly assigned to receive irinotecan 60 mg/m(2) on days 1, 8, and 15 plus cisplatin 60 mg/m(2) on day 1 (CPT-P group) every 4 weeks for six cycles or paclitaxel 175 mg/m(2) plus carboplatin area under the curve 6.0 mg/mL/min on day 1 every 3 weeks for six cycles (TC group). The primary end point was progression-free survival. Secondary end points were overall survival, overall response rate, and adverse events.Six hundred nineteen patients were clinically and pathologically eligible for evaluation. With a median follow-up of 44.3 months, 2-year progression-free survival rates were 73.0% in the CPT-P group and 77.6% in TC group (hazard ratio, 1.17; 95% CI, 0.87 to 1.58; P = .85). Two-year overall survival rates were 85.5% with CPT-P and 87.4% with TC (hazard ratio, 1.13; 95% CI, 0.80 to 1.61; one-sided P = .76). Grade 3/4 anorexia, diarrhea, nausea, vomiting, and febrile neutropenia occurred more frequently with CPT-P, whereas grade 3/4 leukopenia, neutropenia, thrombocytopenia, peripheral sensory neuropathy, and joint pain occurred more frequently with TC.No significant survival benefit was found for CPT-P. Both regimens were well tolerated, but the toxicity profiles differed significantly. Treatment with existing anticancer agents has limitations to improving the prognosis of CCC.
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study
Authors: Marina Bagnoli, Silvana Canevari, Daniela Califano, Simona Losito, Massimo Di Maio, Francesco Raspagliesi, Maria Luisa Carcangiu, Giuseppe Toffoli, Erika Cecchin, Roberto Sorio, Vincenzo Canzonieri, Daniela Russo, Giosué Scognamiglio, Gennaro Chiappetta, Gustavo Baldassarre, Domenica Lorusso, Giovanni Scambia, Gian Franco Zannoni, Antonella Savarese, Mariantonia Carosi, Paolo Scollo, Enrico Breda, Viviana Murgia, Francesco Perrone, Sandro Pignata, Loris De Cecco, Delia Mezzanzanica
Journal: The Lancet Oncology (2016)
Long-term significance of urinary neopterin in ovarian cancer: a study by the Austrian Association for Gynecologic Oncology (AGO)
Authors: B.M. Volgger, G.H. Windbichler, A.G. Zeimet, A.H. Graf, G. Bogner, L. Angleitner-Boubenizek, M. Rohde, U. Denison, G. Sliutz, L.C. Fuith, D. Fuchs, C. Marth
Journal: Annals of Oncology (2016)
Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction
Authors: Thomas A. Gaziano, Gregg C. Fonarow, Brian Claggett, Wing W. Chan, Celine Deschaseaux-Voinet, Stuart J. Turner, Jean L. Rouleau, Michael R. Zile, John J. V. McMurray, Scott D. Solomon
Journal: JAMA Cardiology (2016)

The angiotensin receptor neprilysin inhibitor sacubitril/valsartan was associated with a reduction in cardiovascular mortality, all-cause mortality, and hospitalizations compared with enalapril. Sacubitril/valsartan has been approved for use in heart failure (HF) with reduced ejection fraction in the United States and cost has been suggested as 1 factor that will influence the use of this agent.To estimate the cost-effectiveness of sacubitril/valsartan vs enalapril in the United States.Data from US adults (mean [SD] age, 63.8 [11.5] years) with HF with reduced ejection fraction and characteristics similar to those in the PARADIGM-HF trial were used as inputs for a 2-state Markov model simulated HF. Risks of all-cause mortality and hospitalization from HF or other reasons were estimated with a 30-year time horizon. Quality of life was based on trial EQ-5D scores. Hospital costs combined Medicare and private insurance reimbursement rates; medication costs included the wholesale acquisition cost for sacubitril/valsartan and enalapril. A discount rate of 3% was used. Sensitivity analyses were performed on key inputs including: hospital costs, mortality benefit, hazard ratio for hospitalization reduction, drug costs, and quality-of-life estimates.Hospitalizations, quality-adjusted life-years (QALYs), costs, and incremental costs per QALY gained.The 2-state Markov model of US adult patients (mean age, 63.8 years) calculated that there would be 220 fewer hospital admissions per 1000 patients with HF treated with sacubitril/valsartan vs enalapril over 30 years. The incremental costs and QALYs gained with sacubitril/valsartan treatment were estimated at $35 512 and 0.78, respectively, compared with enalapril, equating to an incremental cost-effectiveness ratio (ICER) of $45 017 per QALY for the base-case. Sensitivity analyses demonstrated ICERs ranging from $35 357 to $75 301 per QALY.For eligible patients with HF with reduced ejection fraction, the Markov model calculated that sacubitril/valsartan would increase life expectancy at an ICER consistent with other high-value accepted cardiovascular interventions. Sensitivity analyses demonstrated sacubitril/valsartan would remain cost-effective vs enalapril.
The Notch Target Genes Hey1 and Hes7 Transcriptionally Suppress Gli1 Expression and Hedgehog Signaling in Hodgkin-Reed/Sternberg Cells of Classical Hodgkin Lymphoma: A Novel Mechanism of Drug Resistance
Authors: Rolf Schwarzer, Julia Godau, Hermann Einsele, Franziska Jundt
Journal: Blood (2014)
Haitian, American Negroes Reveal Differences In Coronary Artery Disease at Adolescence
Authors: A S ZELICKSON, H C ZELLER
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prognostic Factors Associated with Progression of Myelodysplastic Syndromes (MDS) to Acute Myeloid Leukemia (AML) In Patients (pts) Treated with Decitabine
Authors: Amber Fullmer, Guillermo Garcia-Manero, Gautam Borthakur, Tapan Kadia, Hagop Kantarjian, Elias Jabbour
Journal: Blood (2010)
Detection of Leptomeningeal Involvement by 18F-FDG-PET/CT in a Patient With Non-Hodgkin Lymphoma
Authors: Rosa Fonti, Barbara Salvatore, Amalia De Renzo, Emanuele Nicolai, Silvana Del Vecchio
Journal: Clinical Nuclear Medicine (2015)

Leptomeningeal infiltration of the brain or spinal cord by neoplastic cells may occur as complication of solid or hematopoietic tumors such as non-Hodgkin lymphoma. Previously rare, this event is becoming increasingly common as newer therapies can prolong survival but may not achieve therapeutic concentration in the central nervous system. Although prognosis is poor, early diagnosis and aggressive treatment may lead to prolonged survival and/or improvement of quality of life. We report a case of a 69-year-old man with leptomeningeal infiltration by non-Hodgkin lymphoma revealed by 18F-FDG-PET/CT and confirmed by subsequent spinal MRI and cerebrospinal fluid cytology.
In Support of Neuroimaging Biomarkers of Treatment Response in First-Episode Schizophrenia
Authors: Deepak K. Sarpal, Todd Lencz, Anil K. Malhotra
Journal: American Journal of Psychiatry (2016)

ECT at 1.53 threshold, the most commonly used form of bitemporal ECT in recent relevant trials.Nor are there trial data for crossover from bitemporal to high-dose unilateral ECT, which happens occasionally in clinical practice when cognitive side effects are not tolerable.Dr. Kellner and Ms. Farber remind us that in clinical practice we deal with individual patients.One size of ECT clearly does not fit all.Therefore, some clinical judgment, based on available evidence as well as informed patient preference, is required.For severely ill patients with lifethreatening depression, extreme distress, and/or catatonia who typically do not participate in randomized trials, we recommend starting with bitemporal ECT at 1.53 threshold, as this may have a more rapid effect (4).However, non-lifethreatening treatment-resistant depression is a much more common indication for ECT.For such patients, based on the evident ratio of harm to benefit, we would recommend beginning with high-dose unilateral ECT.If the patient feels that there is insufficient benefit, then the patient could be switched to bitemporal ECT, initially at 1.53 threshold.In all these scenarios, if there is no benefit from the crossovers, one could consider 2.53 threshold bitemporal ECT, although there is no evidence that this is better than 1.53 threshold bitemporal ECT.However, it may act more rapidly than bitemporal ECT at just 1.03 threshold (5).